Sepracor Inc. , a Marlborough, Mass., biotechnology company, yesterday suffered a double setback as its experimental depression drug failed a midstage study and US regulators halted two pediatric studies of its blockbuster Lunesta insomnia pill, sending shares down over 15 percent in after-hours trading.

Click Here to read the entire article...